MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
Centers for Disease Control and Prevention
1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium
Atlanta, Georgia 30329
February 27-28, 2019

AGENDA ITEM | PRESIDER/PRESENTER(s)
--- | ---
Wednesday, February 27 | 8:00 Welcome & Introductions | Dr. Jose Romero (ACIP Chair)
Dr. Amanda Cohn (ACIP Executive Secretary; CDC)

8:20 Japanese Encephalitis Vaccine
- Introduction
- Background and review
- Updated recommendations for U.S. travelers
- Accelerated primary series in adults
- Booster dose recommendations
Dr. Chip Walter (ACIP, WG Chair)
Dr. Susan Hills (CDC/NCEZID)

9:20 Break

9:30 Anthrax Vaccines
- Introduction
- AV7909 (NuThrax)
- Preexposure AVA booster dose interval
Dr. David Stephens (ACIP, WG Chair)
Dr. William Bower (CDC/NCEZID)

10:30 Break

10:40 Influenza Vaccines
- Introduction
- Surveillance update
- VE update
- Afluria quadrivalent for children aged 6 through 59 months
- Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink
- Summary and work group considerations
Dr. Chip Walter
Ms. Lynnette Brammer (CDC/NCIRD)
Dr. Brendan Flannery (CDC/NCIRD)
Dr. Gregg Sylvester (Seqirus)
Dr. James Donahue (Marshfield Clinic)
Dr. Lisa Grohskopf (CDC/NCIRD)

12:00 Lunch

1:00 Human Papillomavirus Vaccines
- Introduction
- Impact and cost effectiveness of mid-adult HPV vaccination
- Overview of health economic results from 4 modeling groups
- Mid-adult HPV vaccination: patient values and acceptability
- Program and vaccine provider surveys
- Work group considerations
Dr. Peter Szilagyi (ACIP, WG Chair)
Dr. Lauri Markowitz (CDC/NCIRD)
Dr. Marc Brisson (Laval University)
Dr. Harrell Chesson (CDC/NCHHSTP)
Dr. Nancy McClung (CDC/NCIRD)
Dr. Elissa Meites (CDC/NCIRD)
Dr. Lauri Markowitz (CDC/NCIRD)

2:30 Break

2:40 Combination Vaccines
- Introduction
- Immunogenicity and safety of a pediatric hexavalent vaccine
- Hib vaccines in AI/AN population
- Summary, review of work group considerations
Dr. Kelly Moore (ACIP, WG Chair)
Dr. Andrew Lee (Merck)
Dr. Laura Hammitt (Johns Hopkins University)
Dr. Sara Oliver (CDC/NCIRD)

3:30 Break

3:40 Public Comment

4:55 Break

5:00 VOTES
- Japanese Encephalitis Vaccine
- Anthrax Vaccines
Dr. Susan Hills (CDC/NCEZID)
Dr. William Bower (CDC/NCEZID)

5:30 Adjourn
Thursday, February 28

8:00  Agency Updates & Unfinished Business
      CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO
      Dr. Nancy Messonnier (CDC/NCIRD); Ex Officio Members

8:30  Pneumococcal Vaccines
      Introduction
      PCV13 direct and indirect effects on serotype 3 disease
      Dr. Tamara Pilishvili (CDC/NCIRD)
      PCV13 direct effects on pneumonia hospitalizations in adults
      Dr. Fernanda Lessa (CDC/NCIRD)
      Comparison of economic analyses of PCV13 use among adults ≥65 years old
      Dr. Andrew Leidner (CDC/NCIRD)
      GRADE and Evidence to Recommendations (EtR) for PCV13 use among adults ≥65 years old in the context of indirect effects experience to date
      Dr. Almea Matanock (CDC/NCIRD)

10:30 Break

10:40  Meningococcal Vaccines
      Introduction
      Immunogenicity and safety of a MenB-FHbp booster dose
      Dr. Paul Balmer (Pfizer)
      Immunogenicity and safety of a MenB-4C booster dose
      Dr. Phil Watson (GSK)
      GRADE and Evidence to Recommendations Framework for MenB booster doses
      Dr. Catherine Bozio (CDC/NCIRD)
      Work Group interpretation of data, considerations, and next steps
      Dr. Sarah Mbaeyi (CDC/NCIRD)

11:55 Lunch

1:00  Zoster Vaccines
      Introduction
      Zoster vaccine uptake and supply
      Dr. Kathleen Dooling (CDC/NCIRD)
      RZV safety update
      Dr. Tom Shimabukuro (CDC/NCEZID)

1:40  Hepatitis Vaccines
      Introduction
      Background: HepA vaccines and persons with HIV infection
      Dr. Mark Weng (CDC/NCHHSTP)
      GRADE: Use of HepA vaccines among persons with HIV infection
      Ms. Alaya Koneru (CDC/NCHHSTP)
      Evidence to Recommendation Framework: Use of HepA vaccines among persons with HIV infection
      Dr. Mark Weng (CDC/NCHHSTP)

2:35  Vaccine Supply

2:40 Adjourn

Acronyms
AI/AN  American Indian/Alaska Native
AVA   Anthrax vaccine absorbed
CDC   Centers for Disease Control & Prevention
CMS   Centers for Medicare and Medicaid Services
DoD   Department of Defense
DVA   Department of Veterans Affairs
EtR   Evidence to Recommendations Framework
FDA   Food and Drug Administration
GRADE Grading of Recommendations Assessment, Development and Evaluation
Hib   Haemophilus influenzae type b
HRSA  Health Resources and Services Administration
IHS   Indian Health Service
MenB  Serogroup B meningococcal vaccine
NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NVPO  National Vaccine Program Office
PCV13 13-valent pneumococcal conjugate vaccine
RZV   Recombinant zoster vaccine
WG    Work Group